TrialBreast cancer research : BCR2019

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.

Stephen K L Chia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.